Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

In relapsed or refractory multiple myeloma, talquetamab plus daratumumab with pomalidomide improved progression-free survival versus daratumumab plus pomalidomide and dexamethasone, with 24-month estimates of 81.3% and 77.6%.

• Why it matters: Patients with relapsed or refractory multiple myeloma after at least one prior therapy need better outcomes than standard daratumumab-based regimens, with durable disease control.
• What they did: In a phase 3 randomized trial, patients received Tal-DP, Tal-D, or DPd; progression-free survival was assessed by an independent review committee, with interim analysis at median follow-up of 24.6 months.
• The result: Progression-free survival was significantly longer for Tal-DP and Tal-D than for DPd (hazard ratios 0.28 and 0.33; P<0.001), with higher overall response (88.2% and 88.5%) and complete response or better (71.1% and 69.0%).

AI summary of the abstract · may contain errors · not medical advice · read the paper.